SalvaRx Group plc, formerly 3Legs Resources plc, is an investing company. The Company is engaged in drug discovery and development, focused on immune-oncology. The Company's segment is appraisal of investment targets meeting the Company's investment policy. The Company is focused on evaluation and assessment of investment opportunities in line with the investment policy. Its product is IMM60. It expects the study to evaluate approximately three treatment groups: a control arm using the standard of care (an anti-programmed death (PD)-1 therapy), a trial arm using iOX Therapeutics Ltd's drug (IMM60), and a third arm that will test the combination of IMM60 and an anti-PD1 therapy. 3Legs Management Services US LLC is the subsidiary of the Company.